Triastek utilizes its proprietary Melt Extrusion Deposition (MED®) 3D printing technology to create precise solid dosage forms of pharmaceuticals, enabling tailored drug delivery and improved patient outcomes. The startup addresses challenges in drug formulation and production efficiency, accelerating the development of new medications through continuous manufacturing processes.
Funding
$20.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional pharmaceutical manufacturing processes often struggle to create solid dosage forms with precise drug release profiles and tailored geometries, hindering the development of personalized medicines and efficient drug delivery systems. Existing methods can be inefficient for novel formulations and limit the ability to address specific patient needs.
Solution
Triastek utilizes Melt Extrusion Deposition (MED®) 3D printing technology to manufacture pharmaceutical products with precisely controlled drug release and tailored geometries. This technology enables the creation of customized solid dosage forms, addressing formulation challenges and improving drug delivery. Triastek's approach facilitates the development of novel medications through digital product development and continuous manufacturing processes. The MED® platform allows for precise layer-by-layer deposition of materials, creating objects with well-designed microstructures that control when, where, and how much medicine is released in the body. This enables the design of transformative medicines and tackles challenging formulation problems through collaboration with global pharmaceutical companies.
Target Audience
Triastek's primary customers are global pharmaceutical companies seeking to develop novel drug products, improve existing formulations, and create personalized medicines.
Features
- Melt Extrusion Deposition (MED®) 3D printing technology for precise control over drug release profiles.
- Capability to create customized solid dosage forms with tailored geometries.
- 3DμS®-MR: Microstructure for Modified Release.
- 3DμS®-SE: Microstructure for Solubility Enhancement.
- 3DμS®-CT: Microstructure for Colon Targeting.
- 3DμS®-GR: Microstructure for Gastric Retention.
- 3DμS®-OP: Microstructure for Oral Peptide delivery.
- Digital product development and continuous manufacturing processes.